HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
GlobeNewswire
· Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of..
· Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of..
OAKBROOK TERRACE, Illinois, March 28, 2024 (GLOBE NEWSWIRE) -- Detection of early patient deterioration in the hospital can lead to..
· Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the..